Switching from semaglutide to tirzepatide is one of the most common dose transitions in GLP-1 practice. The SURMOUNT-5 head-to-head trial (2025) demonstrated tirzepatide's superior weight-loss efficacy over semaglutide, and many patients plateaued on semaglutide are candidates. This protocol walks through washout, starting dose, titration, and the GI tolerability math in research context.
Key Takeaways
- No formal washout needed. Both drugs are weekly GLP-1 agonists; direct transition is pharmacologically fine.
- Standard practice: inject tirzepatide 7 days after last semaglutide dose. This maintains the weekly cadence.
- Start tirzepatide at 2.5 mg, not higher. The label requires this even for patients on high-dose semaglutide.
- GI tolerability resets. Prior semaglutide tolerance does not transfer; expect new titration-phase nausea.
- Expected additional loss: 5–8% at steady state. SURMOUNT-5 showed ~20% on tirzepatide vs ~14% on semaglutide.
- Clinical oversight required. This is a prescription-to-prescription transition, not a self-managed switch.
Why switch
Two primary indications:
- Plateau or incomplete response on semaglutide. Patients at or below 10% total weight loss at the 2.4 mg Wegovy dose who want further loss.
- Better response profile sought. SURMOUNT-5 data support tirzepatide's superior average weight loss.
Secondary indications include insurance coverage changes, GI tolerability preference (some patients tolerate tirzepatide's GIP agonism better), and availability.
The research context — SURMOUNT-5 head-to-head
| Metric (72-week endpoint) | Semaglutide 2.4 mg (STEP-1 context) | Tirzepatide 15 mg (SURMOUNT-5) |
|---|---|---|
| Average weight loss | ~14–15% | ~20% |
| >15% weight loss (responders) | ~50% | ~65% |
| >20% weight loss (super-responders) | ~30% | ~55% |
| Nausea | ~44% | ~29% |
| Discontinuation (AE) | ~4.5% | ~7% |
Two takeaways. First, tirzepatide averages roughly 5–6% more weight loss than semaglutide head-to-head. Second, tirzepatide's nausea rate is lower, but overall discontinuation is slightly higher — the AE profile is different, not uniformly better.
Washout — what is actually needed
Neither drug has a drug-drug interaction with the other. Both are weekly GLP-1 (semaglutide) or GLP-1/GIP (tirzepatide) receptor agonists. The standard practice:
- Last semaglutide dose — Day 0.
- First tirzepatide dose — Day 7 (one week later), on the new weekly cadence.
No pharmacokinetic washout beyond the standard weekly interval is required. Semaglutide plasma levels decay naturally over its ~7-day half-life.
Starting dose — why 2.5 mg
The tirzepatide label requires starting at 2.5 mg weekly for 4 weeks regardless of prior GLP-1 exposure. This is a tolerability dose, not an efficacy dose. The reasons:
- GIP receptor agonism adds a GI effect that semaglutide tolerance does not cross-protect against.
- Starting too high produces discontinuation-level nausea in a meaningful fraction of patients.
- Phase 3 trial titration data support the 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg ladder.
Patients coming off high-dose semaglutide often ask to skip to tirzepatide 5 or 7.5 mg. This is off-label and increases discontinuation risk; most clinicians will not do it.
Titration protocol
| Weeks on tirzepatide | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg weekly | Tolerability dose; expect mild GI reset |
| 5–8 | 5 mg weekly | First efficacy dose; weight loss begins |
| 9–12 | 7.5 mg weekly | Hold if GI side effects escalate |
| 13–16 | 10 mg weekly | Common maintenance dose for many patients |
| 17–20 | 12.5 mg weekly | Push if continued loss desired |
| 21+ | 15 mg weekly | SURMOUNT-5 top dose |
Managing the GI reset
Prior semaglutide tolerance does not fully transfer. Patients often report:
- Mild nausea returning at 2.5 mg tirzepatide despite being nausea-free on semaglutide 2.4 mg.
- Different flavor to the nausea — some describe tirzepatide nausea as "deeper" or more fatigued than semaglutide.
- Transient constipation worsening during the 2.5 mg phase.
Management is the same as initial titration: smaller lower-fat meals, hydration, ginger, and ondansetron as needed. Nausea on 2.5 mg typically resolves by week 3–4.
Weight-loss expectations after the switch
Reasonable expectations for a patient switching from semaglutide 2.4 mg (maintenance) to tirzepatide (titrating to 10–15 mg):
- Weeks 1–8 — small transient weight regain is common as tirzepatide titrates up from 2.5 mg.
- Weeks 9–20 — net weight loss resumes once at effective dose.
- Weeks 20–52 — additional 5–8% body weight loss on top of semaglutide baseline is a reasonable average expectation.
When not to switch
Not every semaglutide patient benefits from switching. Reasons to stay on semaglutide:
- Already at goal weight with good maintenance on semaglutide.
- Semaglutide tolerated poorly (nausea, GI) — tirzepatide can be harder to tolerate initially despite better long-term AE profile.
- Insurance covers Wegovy but not Zepbound at an acceptable copay.
- Cardiovascular indication established on semaglutide (SUSTAIN-6 CV benefit) that is not yet established on tirzepatide at the equivalent dose.
Conclusion
Switching from semaglutide to tirzepatide is a straightforward prescription-to-prescription transition. Standard practice is to inject the first tirzepatide dose 7 days after the last semaglutide dose, start at 2.5 mg, and titrate through the full label ladder. Prior semaglutide tolerance does not transfer, and the first 4 weeks typically include mild GI reset. Expected additional weight loss averages 5–8% at steady state, with better response for sub-maximal semaglutide users. This is a clinician-managed transition; dose selection and timing should be verified against the current label at the time of switch.
Frequently Asked Questions
How long after my last Ozempic dose can I start tirzepatide?
Standard practice is 7 days — one weekly cycle. No formal washout beyond that is required.
Can I skip the 2.5 mg starting dose on tirzepatide?
Off-label, some clinicians allow starting at 5 mg for patients coming off high-dose semaglutide, but the label requires 2.5 mg × 4 weeks. Skipping it increases discontinuation risk.
Will I lose weight faster on tirzepatide?
Generally yes, but with a lag. SURMOUNT-5 showed tirzepatide produced ~20% weight loss vs ~14% for semaglutide at 72 weeks. The curve begins slowly during the 2.5 mg titration phase.
Does tirzepatide have fewer side effects than Ozempic?
Nausea rates are slightly lower in head-to-head trials, but overall discontinuation for AEs is similar or slightly higher. The profiles are different, not uniformly better.
Will I regain weight switching from Ozempic to tirzepatide?
Small transient regain of 1–3% during the 2.5 mg titration phase is common; net loss resumes once at 7.5 mg or higher.
Is switching from Ozempic to Mounjaro the same as to Zepbound?
Mechanistically yes — both are tirzepatide. Zepbound is the obesity label (max 15 mg) and Mounjaro the T2D label (max 15 mg); both support the same titration ladder.
Primary sources:
- SURMOUNT-5: tirzepatide vs semaglutide — NEJM 2025
- Zepbound (tirzepatide) prescribing information
- Wegovy (semaglutide) prescribing information
- SURMOUNT-1: tirzepatide in obesity — NEJM 2022
- STEP-1: semaglutide in obesity — NEJM 2021
Research disclaimer: This article is a research review for educational use only. It is not medical advice. Switching GLP-1 agents is a clinician-managed transition; dose selection and timing should be verified with a licensed prescriber at the time of switch.
Sources & Further Reading
Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384:989–1002. Phase 3 RCT
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389:2221–2232. Phase 3 RCT
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 387:205–216. Phase 3 RCT